From food and pharmaceuticals to defence technology, Vassilis Katsos is building an investment portfolio through VNK and Concordia Healthcare Partners, with international expansion as its common thread. Three markets, different business cycles and a single strategy: creating companies with greater scale, a stronger export presence and access to new capital.
Pallirroia has its sights set on the Athens Exchange, as Euro2day.gr has reported. At ALTUS-LSA, the agreement with US company Shield AI opens up new prospects in the unmanned systems market.
In pharmaceuticals, Concordia Healthcare Partners, the investment fund set up by Vassilis Katsos and Periklis Vasilopoulos, is looking for its next acquisition target in Europe.
As for Pallirroia, sources familiar with the matter tell Euro2day.gr that an exploration of the available options is expected to begin in 2027, with advisers involved. A possible listing is envisaged for late 2027 or early 2028. The decision will depend on the company’s performance, capital market conditions and valuations. Mr Katsos remains a shareholder through VNK Capital, as the agreement to sell the 36% stake was not completed.
In contrast with Pallirroia’s mature industrial business, ALTUS-LSA operates in one of the fastest-growing and most technologically demanding sectors. Unmanned defence systems.
The agreement with US company Shield AI marks a pivotal development. It provides for the integration of the KMB Hunter interception system and the M3NTOR command-and-control platform with the US company’s V-BAT unmanned aircraft and Hivemind autonomy software. Sources familiar with the matter also say that further partnerships are under consideration, with Katsos betting on the potential to expand the company’s presence in the international defence industry.
The third pillar of the investment plan is in a sector Vassilis Katsos knows well. Very well. Pharmaceuticals. Through Concordia Healthcare Partners, which he set up with Periklis Vasilopoulos, he aims to capitalise on the opportunities created by the fragmented European pharmaceutical market.
With a presence in Athens and London, Concordia focuses on small and mid-sized growth companies with specialised expertise, production capabilities and potential for international expansion. Its strategy is based on acquisitions and the creation of larger business groups, able to benefit from economies of scale and new commercial partnerships.
The investment in Icelandic company Coripharma reflects this strategy. The next step is to expand the portfolio through further acquisitions in Europe.